Naila Goldenberg, MD
Endocrinology, Diabetes & Metabolism · Mason, OHNPI 1396796330
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $23,930 of the $36,571 with a category attached, or 65.4%. 60 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 26.1% of the total. Reporting peaked in 2019 at $17,158 and has fallen 82.7% since, to $2,968 in 2025.
Across 1,435 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$10K
- Regeneron Healthcare Solutions, Inc.$4K
- Novo Nordisk$2K
- Corcept Therapeutics$2K
- Lilly USA, LLC$2K
- Amgen$2K
- plus $14K from 54 others
Across 6 payments — averaging $1841.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$11K
What the payments were for
- Consulting fees$3251%
- Speaking & faculty fees$10,89930%
- Travel & lodging$1,3064%
- Food & beverage$23,93065%
- Education$1110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$11,792
- Korlym$1,226
- iLet Bionic Pancreas$441
- EVENITY$282
- Minimed 670G System$258
- Tirosint$125
- Vascepa$125
- RYBELSUS$122
- SOLIQUA 100/33$121
- Wegovy$121
- RECORLEV$119
- TEPEZZA$114
- Omnipod$113
- TZIELD$111
- DEXCOM CGM$108
- MINIMED 780G$102
- MOUNJARO$100
- Strensiq$100
- FARXIGA$100
How this compares
$36,571 in reported general payments places this provider in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 22 | $625,978 |
| OzempicSemaglutide | 28 | $40,249 |
| VascepaIcosapent Ethyl | 46 | $33,588 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $30,752 |
| TrulicityDulaglutide | 12 | $29,069 |
| JardianceEmpagliflozin | 18 | $28,989 |
| Repatha SureclickEvolocumab | 27 | $27,700 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $17,750 |
| Teriparatide | 13 | $13,005 |
| Solu-CortefHydrocortisone Sodium Succ/Pf | 24 | $10,259 |
| Solu-CortefHydrocortisone Sod Succinate | 12 | $9,240 |
| Buprenorphine Hcl | 119 | $8,359 |
| Liothyronine Sodium | 51 | $2,992 |
| Tirosint-SolLevothyroxine Sodium | 11 | $2,515 |
| Np ThyroidThyroid,pork | 12 | $1,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $2,006 | $625,97822 claims |
| Novo NordiskOzempic | $2,487 | $40,24928 claims |
| Lilly USA, LLCTrulicity | $2,075 | $29,06912 claims |
| Boehringer IngelheimJardiance | $568 | $28,98918 claims |
| Alvogen IncTeriparatide | $23 | $13,00513 claims |
| IBSA Pharma Inc.Tirosint-Sol | $284 | $2,51511 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $71 | $1,48112 claims |
| PfizerLevoxyl | $153 | $72115 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $105 | $61681 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Mason
- Lina MitchellMason$22K
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Nelson WattsCincinnati$346K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.